ClinicalTrials.gg
Not yet recruitingNCT07398404Updated Jul 8, 2026

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

A Phase 1/2 interventional study of Naltrexone hydrochloride and Bupropion Hydrochloride Extended-release in Obesity, Smoking Cessation and Bariatric Surgery Patients, sponsored by Medical University of South Carolina. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Medical University of South Carolina · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Planned enrollment
13th of 23
64 · median 67
Started
2026
with 2 others
Phase 1/2
Only one
of the 23
Registered
23rd of 23
by date
Lead sponsor
2 of 23
Medical University of South Carolina

Among the 23 studies testing naltrexone in Obesity, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 23rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery. The intervention will be compared to a standard of care control group.

Read the detailed description

Smoking prevalence among pre-bariatric surgery patients is estimated to be as high as 40%. In addition to quitting smoking, patients are expected to lose weight before surgery, which is challenging as smoking cessation is associated with weight gain. This study aims to evaluate a multiple health behavior change intervention with combined behavioral and pharmacotherapy (Naltrexone/Bupropion) for weight loss and smoking cessation for adults seeking bariatric surgery. This pilot randomized control trial will evaluate feasibility and acceptability of the intervention and compare the intervention to a standard of care control group.

03

Conditions studied

  • Obesity
  • Smoking Cessation
  • Bariatric Surgery Patients
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18-65 years old.
  • Be actively considering bariatric surgery.
  • Smoke at least 5 cigarettes daily for the past 3 months.
  • Have a ≥ 30.0 kg/m2.
  • Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines).
  • No history of medical conditions that are with Naltrexone or - Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa).
  • Physically well enough to participate in the intervention (e.g., able to walk independently).
  • Speak/read/write in English.
  • Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study.
  • No active suicidal or homicidal ideation.

Exclusion criteria

Exclusion Criteria:

  • Has an acute medical or psychiatric disorder that would make participation difficult or unsafe.
  • Has suicidal or homicidal ideation that requires immediate attention.
  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Has evidence of a second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the , or any other finding on the screening that would preclude safe participation.
  • Has stage 2 hypertension (blood pressure greater than 160/100 or heart rate over 100 beats/minute).
  • Has elevated test or any other liver function test value > 5 times the laboratory criteria.
  • Has a count \< 100x10 3/uL.
  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Is currently taking a medication that is to Naltrexone or Bupropion (e.g., MAOIs, opiates).
  • Has a history of allergy or sensitivity to Naltrexone or Bupropion.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression).
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled Type I or Type 2 diabetes mellitus.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder, including cancer.
  • Has angle closure glaucoma.
  • Has taken an drug in another study within 30 days of study consent.
  • Has been prescribed and taken Naltrexone or Bupropion within 30 days of study consent.
  • Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder treatment.
  • Is receiving ongoing treatment with tricyclic antidepressants, xanthines, systemic , nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous stimulants, or any medication that could interact adversely with the study medications.
  • Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study.
  • Requires treatment with opioid-containing medications during the study period.
  • Has a surgery planned other than bariatric surgery.
  • Is currently in jail, prison, or any inpatient overnight facility as required by a court of law or have pending legal action or other legal situation that could prevent participation.
  • Is currently pregnant, breastfeeding, or plans to become pregnant during the study, or is not using a reliable form of .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    MHBC Intervention Group

    Participants will receive the multiple health behavior intervention with combined behavioral and pharmacotherapy (Naltrexone/Bupropion).

    Drug: Naltrexone hydrochloride · Drug: Bupropion Hydrochloride Extended-release · Behavioral: Cognitive-Behavioral Therapy

  • No intervention
    Control Group

    Participants will receive the current standard of care treatments and services offered by the bariatric clinic for weight loss and smoking cessation.

Interventions

  • DrugNaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be given 50mg/day of Naltrexone for 4 months.

  • DrugBupropion Hydrochloride Controlled-releaseStudies of Bupropion Hydrochloride Controlled-releaseBupropion Hydrochloride Controlled-release pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be given 300mg/day of Bupropion for 4 months. Bupropion will be taken twice daily (150mg in the morning, followed by 150mg in the late afternoon/early evening).

  • BehavioralCognitive-Behavioral Therapy

    Participants will receive cognitive-behavioral therapy for weight loss and smoking cessation. Participants will meet with their assigned study clinician weekly for 60 minutes for 4 months.

06

What researchers measure

Primary outcomes

  1. Study enrollment to assess Feasibility

    Number of participants enrolled out of participants screened.

    Time frame: 16 weeks

  2. Mean number treatment sessions attended to assess Feasibility

    Mean number of treatment sessions attended.

    Time frame: 16 weeks

  3. Retention to assess Feasibility

    Retention will be measured as the percent of participants that attend the post treatment assessment.

    Time frame: 16 weeks

  4. Treatment credibility to assess Acceptability

    Treatment credibility will be assessed via self-report monthly. Acceptability measured as the percent of participants that agree the intervention is acceptable (0-100%, with higher scores being indicative of higher treatment credibility).

    Time frame: Week 4, Week 8, Week 12, Week 16

  5. Treatment satisfaction to assess Acceptability

    Treatment satisfaction will be assessed via self-report at post-treatment. Acceptability measured as the percent of participants that agree the intervention is satisfactory (0-100%, with higher scores being indicative of higher treatment satisfaction).

    Time frame: Week 16

  6. Percent weight change

    Percent weight change will be calculated from baseline to post-treatment, and post-treatment to 6-month follow-up.

    Time frame: Baseline, Week 16, 6-month follow-up

  7. Smoking cessation, as measured by exhaled carbon monoxide

    Smoking cessation will be evaluated biochemically, through mean exhaled carbon monoxide concentration.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, 6-month follow-up

  8. Smoking cessation, as measured by timeline followback interview

    Smoking cessation will be evaluated behaviorally, through point prevalence abstinence data obtained by timeline followback interviews.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, 6-month follow-up

Secondary outcomes

  1. Nicotine dependence, as measured by the Fagerstrom Test for Nicotine Dependence

    The Fagerstrom Test for Nicotine Dependence is a self-report measure that classifies level of nicotine dependence. Participants respond to a series of questions assessing time of first cigarette after waking, difficulty refraining from smoking in places where smoking is prohibited, and frequency of smoking. Total score range 0-10 with higher scores indication more nicotine dependence.

    Time frame: Baseline, Week 16, 6-month follow-up

  2. Depressive symptomatology, as measured by the Patient Health Questionnaire-9

    The Patient Health Questionnaire-9 is a brief, psychometrically sound, and widely used self-report measure of depression in diverse medical settings. The total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline, Week 16, 6-month follow-up

  3. Physical activity, as measured by the Global Physical Activity Questionnaire (GPAQ)

    GPAQ is a validated self-report assessment of physical activity and sedentary behavior. GPAQ does not have a single fixed total score range but a score is calculated in METs-minutes per day. Participants are classified as "active" if they meet or exceed 600 METs-minutes per week.

    Time frame: Baseline, Week 16, 6-month follow-up

  4. Number of participants with Bariatric surgery completion

    Bariatric surgery completion will be assessed at 6-month follow-up, through medical record review.

    Time frame: 6-month follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Chow A, Neville A, Kolozsvari N. Smoking in bariatric surgery: a systematic review. Surg Endosc. 2021 Jun;35(6):3047-3066. doi: 10.1007/s00464-020-07669-3. Epub 2020 Jun 10. PubMed 32524412 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2030, 51 months later.

Of 39 non-industry phase 1/2 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 51 months is above that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 14 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 9, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jun 30, 2031
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07398404
Responsible party
Caitlin Smith (Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Feb 9, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jul 8, 2026

Study contacts

Caitlin E Smith, PhD
Contact
smithcai@musc.edu
203-785-7210
Caitlin E Smith, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion Hydrochloride Controlled-release

Start the discussion